OmniAb, Inc. (NASDAQ:OABIW – Get Free Report) was the recipient of a significant decline in short interest during the month of May. As of May 29th, there was short interest totaling 9,581 shares, a decline of 33.6% from the May 14th total of 14,433 shares. Based on an average daily volume of 8,727 shares, the days-to-cover ratio is currently 1.1 days.
OmniAb Stock Down 13.2%
Shares of OABIW stock traded down $0.01 during mid-day trading on Wednesday, hitting $0.09. The company’s stock had a trading volume of 6,640 shares, compared to its average volume of 9,268. OmniAb has a 52-week low of $0.05 and a 52-week high of $0.30. The business has a 50-day moving average price of $0.10 and a 200 day moving average price of $0.10.
About OmniAb
OmniAb, Inc is a clinical‐stage biotechnology company specializing in the discovery and optimization of therapeutic antibodies. The company leverages a broad suite of proprietary platform technologies designed to accelerate antibody generation, characterization, and engineering. By integrating advanced immunization methods with high‐throughput screening and bioinformatics, OmniAb aims to streamline the development of next‐generation biologics across a range of disease areas.
At the core of OmniAb’s offering are its transgenic animal platforms, which have been engineered to produce fully human antibodies, and its complementary in vitro display and single‐cell screening capabilities.
Featured Stories
- Five stocks we like better than OmniAb
- After SpaceX, Amazon Could Be The Next Best Space Stock
- 3 Stocks to Watch If the Strait of Hormuz Reopens
- Draining the Tank: Big Oil Runs on Fumes
- Microsoft’s Xbox Problem Is Bigger Than a Console War
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.
